Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils.

van Spriel AB, van den Herik-Oudijk IE, van Sorge NM, Vilé HA, van Strijp JA, van de Winkel JG.

J Infect Dis. 1999 Mar;179(3):661-9.

PMID:
9952373
2.

FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.

Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG.

Blood. 1997 Dec 1;90(11):4485-92.

3.

Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.

Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T.

J Immunol. 2000 Nov 15;165(10):5954-61.

4.

Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.

Heijnen IA, Rijks LJ, Schiel A, Stockmeyer B, van Ojik HH, Dechant M, Valerius T, Keler T, Tutt AL, Glennie MJ, van Royen EA, Capel PJ, van de Winkel JG.

J Immunol. 1997 Dec 1;159(11):5629-39.

PMID:
9548506
5.

Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).

van Egmond M, van Spriel AB, Vermeulen H, Huls G, van Garderen E, van de Winkel JG.

Cancer Res. 2001 May 15;61(10):4055-60.

6.

Effective targeting of pathogens to neutrophils via chimeric surfactant protein D/anti-CD89 protein.

Tacken PJ, Hartshorn KL, White MR, van Kooten C, van de Winkel JG, Reid KB, Batenburg JJ.

J Immunol. 2004 Apr 15;172(8):4934-40.

7.

Neutrophil Fc gamma RI as target for immunotherapy of invasive candidiasis.

van Spriel AB, van den Herik-Oudijk IE, van de Winkel JG.

J Immunol. 2001 Jun 15;166(12):7019-22.

8.

Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.

Stockmeyer B, Elsässer D, Dechant M, Repp R, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T.

J Immunol Methods. 2001 Feb 1;248(1-2):103-11.

PMID:
11223072
9.

Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18).

van Egmond M, van Vuuren AJ, Morton HC, van Spriel AB, Shen L, Hofhuis FM, Saito T, Mayadas TN, Verbeek JS, van de Winkel JG.

Blood. 1999 Jun 15;93(12):4387-94.

11.

Targeting of Porphyromonas gingivalis with a bispecific antibody directed to FcalphaRI (CD89) improves in vitro clearance by gingival crevicular neutrophils.

Kobayashi T, Takauchi A, van Spriel AB, Vilé HA, Hayakawa M, Shibata Y, Abiko Y, van de Winkel JG, Yoshie H.

Vaccine. 2004 Dec 16;23(5):585-94.

PMID:
15542178
12.
13.

FcR gamma-chain dependent signaling in immature neutrophils is mediated by FcalphaRI, but not by FcgammaRI.

Otten MA, Leusen JH, Rudolph E, van der Linden JA, Beelen RH, van de Winkel JG, van Egmond M.

J Immunol. 2007 Sep 1;179(5):2918-24.

14.
15.

Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors.

Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, Beelen RH, van de Winkel JG, van Egmond M.

J Immunol. 2005 May 1;174(9):5472-80.

16.
17.

Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.

Stockmeyer B, Valerius T, Repp R, Heijnen IA, Bühring HJ, Deo YM, Kalden JR, Gramatzki M, van de Winkel JG.

Cancer Res. 1997 Feb 15;57(4):696-701.

19.

Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells.

Sundarapandiyan K, Keler T, Behnke D, Engert A, Barth S, Matthey B, Deo YM, Graziano RF.

J Immunol Methods. 2001 Feb 1;248(1-2):113-23.

PMID:
11223073
20.

Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans.

Monari C, Casadevall A, Retini C, Baldelli F, Bistoni F, Vecchiarelli A.

AIDS. 1999 Apr 16;13(6):653-60.

PMID:
10397559

Supplemental Content

Support Center